Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780736 | 1.00 | MEN1 (0.47) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4781928 | 0.84 | SMN1; SMN2 (0.59) | MEN1KMT2AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL14169206 | 0.83 | MEN1 (0.48) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4728379 | 0.78 | MEN1 (0.51) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4728377 | 0.78 | MEN1 (0.51) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL14164036 | 0.77 | SMN1; SMN2 (0.48) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL2190710 | 0.76 | L3MBTL1 (0.62) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4783316 | 0.76 | KMT2A (0.47) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4783320 | 0.76 | KMT2A (0.47) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL2190712 | 0.76 | L3MBTL1 (0.62) | MEN1KMT2AMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008036652-A2 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | MEN1 1795/4885KMT2A 636/4885MAPT 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.